MX9805196A - Composiciones secas. - Google Patents
Composiciones secas.Info
- Publication number
- MX9805196A MX9805196A MX9805196A MX9805196A MX9805196A MX 9805196 A MX9805196 A MX 9805196A MX 9805196 A MX9805196 A MX 9805196A MX 9805196 A MX9805196 A MX 9805196A MX 9805196 A MX9805196 A MX 9805196A
- Authority
- MX
- Mexico
- Prior art keywords
- hydrophobic
- present
- dry composition
- group
- pharmacologically active
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1658—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
Abstract
El objetivo de esta invencion es proveer una composicion seca que tiene las siguientes propiedades ventajosas; es decir, incluso cuando se deja en un ambiente altamente humedo, la composicion seca de esta invencion escasamente pierde su actividad farmacéutica, no se delicua y retiene su estado seco durante un periodo prolongado; una composicion seca de esta invencion consiste en por lo menos uno de los ingredientes activos seleccionados del grupo que consiste en proteínas farmacologicamente activas y polipéptidos farmacologicamente activas y como un estabilizador por lo menos uno de los estabilizadores hidrofobicos seleccionados del grupo consistiendo en aminoácidos hidrofobicos, dipeptidos hidrofobicos y tripeptidos hidrofobicos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP33671495 | 1995-12-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
MX9805196A true MX9805196A (es) | 1998-10-31 |
Family
ID=18302038
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX9805196A MX9805196A (es) | 1995-12-25 | 1998-06-25 | Composiciones secas. |
Country Status (16)
Country | Link |
---|---|
EP (2) | EP0869816B1 (es) |
JP (2) | JP3208441B2 (es) |
KR (1) | KR100461291B1 (es) |
CN (1) | CN101279095A (es) |
AR (1) | AR005274A1 (es) |
AT (2) | ATE387188T1 (es) |
AU (1) | AU705094B2 (es) |
BR (1) | BR9612236A (es) |
CA (1) | CA2241179C (es) |
DE (2) | DE69634046T2 (es) |
DK (2) | DK0869816T3 (es) |
ES (2) | ES2300667T3 (es) |
MX (1) | MX9805196A (es) |
PT (2) | PT1424066E (es) |
TW (1) | TW403653B (es) |
WO (1) | WO1997023239A1 (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6582728B1 (en) | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
CA2301889C (en) * | 1998-06-26 | 2008-02-19 | Otsuka Pharmaceutical Co., Ltd. | Water-soluble dry compositions |
ATE313318T1 (de) * | 1999-10-29 | 2006-01-15 | Nektar Therapeutics | Trockenpulverzusammensetzungen mit verbesserter dispersität |
CA2395438C (en) * | 1999-12-24 | 2009-10-13 | Otsuka Pharmaceutical Co., Ltd. | Dry compositions containing hydrophobic amino acid |
US7262317B2 (en) | 2000-07-24 | 2007-08-28 | Ono Pharmaceuticals Co., Ltd. | Freeze-dried preparation of n[o-(p-pivaloyloxybenzenasulfonylamino) benzoyl] glycine monosodium salt tetrahydrate and process for producing same |
EP1356809A4 (en) * | 2000-12-28 | 2008-05-14 | Takeda Pharmaceutical | SUSTAINED RELEASE PREPARATIONS |
EG24184A (en) | 2001-06-15 | 2008-10-08 | Otsuka Pharma Co Ltd | Dry powder inhalation system for transpulmonary |
KR100815216B1 (ko) * | 2001-06-15 | 2008-03-19 | 오츠카 세이야쿠 가부시키가이샤 | 경폐 투여용 건조 분말 흡입 시스템 |
BR0306741A (pt) | 2002-02-22 | 2004-12-28 | Ajinomoto Kk | Método para produzir um pó de aminoácidos, e, pó de aminoácidos |
WO2004028557A1 (ja) * | 2002-09-26 | 2004-04-08 | Shionogi & Co., Ltd. | 安定化されたタンパク組成物 |
DK1575531T3 (da) * | 2002-09-27 | 2011-11-21 | Biogen Idec Inc | Terapier for kronisk inflammatorisk demyeliniserende polyneuropati under anvendelse af interferon-beta |
DE102004022927A1 (de) * | 2004-05-10 | 2005-12-15 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 1,4 O-verknüpfte Saccharose-Derivate zur Stabilisierung von Antikörpern oder Antikörper-Derivaten |
JPWO2006062238A1 (ja) * | 2004-12-07 | 2008-06-12 | 味の素株式会社 | アミノ酸の微粉末及びその懸濁液 |
MY139088A (en) * | 2005-02-21 | 2009-08-28 | Lg Life Sciences Ltd | Sustained release composition of protein drug |
JP5034944B2 (ja) * | 2005-07-27 | 2012-09-26 | 味の素株式会社 | インターフェロン作用物質の活性増強剤 |
EP2167686A1 (en) * | 2007-06-16 | 2010-03-31 | Enigma Diagnostics Ltd. | Compositions |
MX2016000739A (es) * | 2013-07-18 | 2017-04-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
CN104472877B (zh) * | 2014-12-17 | 2017-07-18 | 宁夏伊品生物科技股份有限公司 | L‑赖氨酸制品的制备工艺 |
WO2018113891A1 (en) * | 2016-12-23 | 2018-06-28 | University Of Copenhagen | A co-amorphous form of a substance and a dipeptide |
JP7149630B2 (ja) | 2021-01-14 | 2022-10-07 | 株式会社G.A.Yellows | 樹脂リム一体型金属眼鏡フレーム |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0341033A (ja) * | 1989-07-07 | 1991-02-21 | Kyowa Hakko Kogyo Co Ltd | 安定なモチリン類含有製剤 |
US5496559A (en) * | 1991-04-08 | 1996-03-05 | Sumitomo Pharmaceuticals Company, Limited | Porous solid formulations containing proteinaceous physiologically active substances |
US6582728B1 (en) * | 1992-07-08 | 2003-06-24 | Inhale Therapeutic Systems, Inc. | Spray drying of macromolecules to produce inhaleable dry powders |
ES2245780T3 (es) * | 1994-05-18 | 2006-01-16 | Nektar Therapeutics | Metodos y composiciones para la formulacion de interferones como un polvo seco. |
US6117455A (en) * | 1994-09-30 | 2000-09-12 | Takeda Chemical Industries, Ltd. | Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent |
-
1996
- 1996-12-24 TW TW085116021A patent/TW403653B/zh not_active IP Right Cessation
- 1996-12-25 DE DE69634046T patent/DE69634046T2/de not_active Expired - Lifetime
- 1996-12-25 DE DE69637450T patent/DE69637450T2/de not_active Expired - Lifetime
- 1996-12-25 DK DK96942636T patent/DK0869816T3/da active
- 1996-12-25 KR KR10-1998-0704875A patent/KR100461291B1/ko not_active IP Right Cessation
- 1996-12-25 AT AT04002580T patent/ATE387188T1/de active
- 1996-12-25 AT AT96942636T patent/ATE284713T1/de active
- 1996-12-25 AU AU11732/97A patent/AU705094B2/en not_active Ceased
- 1996-12-25 PT PT04002580T patent/PT1424066E/pt unknown
- 1996-12-25 CA CA2241179A patent/CA2241179C/en not_active Expired - Fee Related
- 1996-12-25 EP EP96942636A patent/EP0869816B1/en not_active Expired - Lifetime
- 1996-12-25 DK DK04002580T patent/DK1424066T3/da active
- 1996-12-25 WO PCT/JP1996/003772 patent/WO1997023239A1/en active IP Right Grant
- 1996-12-25 ES ES04002580T patent/ES2300667T3/es not_active Expired - Lifetime
- 1996-12-25 CN CNA2008100870983A patent/CN101279095A/zh active Pending
- 1996-12-25 PT PT96942636T patent/PT869816E/pt unknown
- 1996-12-25 EP EP04002580A patent/EP1424066B1/en not_active Expired - Lifetime
- 1996-12-25 ES ES96942636T patent/ES2233983T3/es not_active Expired - Lifetime
- 1996-12-25 JP JP34505496A patent/JP3208441B2/ja not_active Expired - Fee Related
- 1996-12-25 BR BR9612236A patent/BR9612236A/pt not_active IP Right Cessation
- 1996-12-26 AR ARP960105889A patent/AR005274A1/es active IP Right Grant
-
1998
- 1998-06-25 MX MX9805196A patent/MX9805196A/es not_active IP Right Cessation
-
2000
- 2000-12-27 JP JP2000398486A patent/JP4099623B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
ES2300667T3 (es) | 2008-06-16 |
ATE284713T1 (de) | 2005-01-15 |
DE69634046D1 (de) | 2005-01-20 |
JP4099623B2 (ja) | 2008-06-11 |
JP2001172198A (ja) | 2001-06-26 |
ATE387188T1 (de) | 2008-03-15 |
EP0869816A1 (en) | 1998-10-14 |
DK0869816T3 (da) | 2005-01-31 |
KR19990076752A (ko) | 1999-10-15 |
PT1424066E (pt) | 2008-04-23 |
AU705094B2 (en) | 1999-05-13 |
ES2233983T3 (es) | 2005-06-16 |
JP3208441B2 (ja) | 2001-09-10 |
JPH09235238A (ja) | 1997-09-09 |
EP0869816B1 (en) | 2004-12-15 |
BR9612236A (pt) | 1999-07-13 |
KR100461291B1 (ko) | 2005-02-28 |
DE69637450D1 (de) | 2008-04-10 |
CA2241179C (en) | 2010-10-19 |
WO1997023239A1 (en) | 1997-07-03 |
DE69634046T2 (de) | 2005-12-22 |
AU1173297A (en) | 1997-07-17 |
DK1424066T3 (da) | 2008-05-26 |
AR005274A1 (es) | 1999-04-28 |
CN101279095A (zh) | 2008-10-08 |
EP1424066A1 (en) | 2004-06-02 |
TW403653B (en) | 2000-09-01 |
DE69637450T2 (de) | 2009-02-19 |
PT869816E (pt) | 2005-03-31 |
CA2241179A1 (en) | 1997-07-03 |
EP1424066B1 (en) | 2008-02-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX9805196A (es) | Composiciones secas. | |
PT948358E (pt) | Formulacoes de interferao liquidas e estaveis | |
YU71395A (sh) | Acilovani analozi insulina | |
PT883687E (pt) | Receptores de quimiocinas c-c, ckr-5, cc, os seus derivados e as suas utilizacoes | |
HUP0003592A2 (hu) | LH-RH peptid analógok, alkalmazásuk, és ezeket tartalmazó gyógyászati készítmények | |
MX9702146A (es) | Preparaciones de enzimas estabilizadas con sal. | |
MX9502034A (es) | Formulacion estable, liofilizada, que comprende una proteina y equipo de dosificacion. | |
NZ502872A (en) | Mevinolin and compaction as LFA-1 antagonists for treating autoimmune diseases | |
CA2139725A1 (en) | Endoparasiticidal compositions | |
WO1996028470A3 (en) | Peptide analogues of human myelin basic protein useful in treating multiple sclerosis | |
CA2287534A1 (en) | Biodegradable microparticles for the sustained delivery of therapeutic drugs | |
HUT58765A (en) | Process for producing peptide compounds and pharmaceutical compositions containing them as active components | |
EP0082568A3 (en) | Retro-inverso analogues of c-terminal penta and hexapeptides of substance p. | |
CA2295628A1 (en) | Stable formulations comprising a nucleotide and a freeze drying additive | |
MY121982A (en) | Pharmaceutical compositions for freeze drying | |
CA2301175A1 (en) | Collagen mimics | |
CA2071757A1 (en) | Implant compositions containing a biologically active protein, peptide or polypeptide | |
NZ334714A (en) | Liver proteins as agents against autoimmune diseases | |
DE3569541D1 (en) | Pharmacologically active peptides | |
BG103412A (en) | Stabilized pharmaceutical compositions based on chinupristine and dalfopristine and their preparation | |
CA2373827A1 (en) | Endoparasiticidal synergistic combination containing cyclic depsipeptides and piperazines | |
AU7209594A (en) | Anti-inflammatory peptides | |
DE59908481D1 (de) | Wasch- und reinigungsmittelformkörper/verpackung-kombination | |
KR970058720A (ko) | 향균 및 항진균 활성을 갖는 펩타이드 | |
NO931745L (no) | Stabiliserte, sterkt virkende grf-analoger |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration | ||
MM | Annulment or lapse due to non-payment of fees |